Welcome to our dedicated page for NEXGEL SEC filings (Ticker: NXGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NexGel, Inc. filings document the formal disclosures of a Nasdaq-listed operating company focused on hydrogel-based healthcare, beauty and OTC products. Recent 8-K reports cover material definitive agreements, an exclusive license and asset purchase for regenerative biomaterial products, convertible-note financing, and capital-structure terms tied to common stock, notes and warrants.
The filings also record board and financial officer changes, employment and compensation arrangements, Nasdaq listing-compliance notices, Regulation FD communications, and exhibits to material contracts. These disclosures connect NexGel’s product expansion, financing activity, governance structure and public-company reporting obligations.
NexGel, Inc. plans a special stockholder vote on an Authorized Share Increase. The proposal asks investors to approve—if and only if the Board later approves and implements—an amendment to raise authorized common stock from 25,000,000 to 1,000,000,000 shares, with total authorized capital increasing to 1,005,000,000 shares. The Board unanimously recommends a “FOR” vote.
The company cites future flexibility for capital raising, acquisitions, partnerships, and other corporate needs. Existing rights of common stock would remain the same, and preferred stock authorization stays at 5,000,000. The filing notes potential dilution if additional shares are issued in the future and acknowledges possible anti‑takeover effects, while stating the proposal is not in response to any control effort. Stockholders of record as of October 20, 2025 may vote; 8,142,766 common shares were outstanding as of that date.
NexGel, Inc. is asking stockholders to approve a major increase in authorized common shares—from 25,000,000 to 1,000,000,000—“if and only if” the Board later approves and implements the change. The vote will be held at 10:00 a.m. ET on November 26, 2025, at the company’s Langhorne, PA headquarters.
The Board unanimously recommends a “FOR” vote. The proposal requires the affirmative vote of a majority of total outstanding shares entitled to vote. Brokers have discretionary authority to vote on this proposal, and no appraisal rights apply.
The company cites future flexibility to raise capital, pursue acquisitions, joint ventures, and other corporate needs. The amendment itself has no immediate effect on ownership or voting power, but future issuances could dilute existing holders. As of October 20, 2025, shares outstanding were 8,142,766. If approved, the Board may effect the increase within twelve months by filing a Certificate of Amendment with Delaware.
NEXGEL, Inc. (NXGL) director Robert Henry Scott reported open-market sales under a Rule 10b5-1 plan. The earliest transaction date is 10/02/2025. He sold 825 shares on 10/02/2025 at $2.50 per share and 7,175 shares on 10/03/2025 at a weighted average price of $2.5502, reducing his direct holdings from 120,531 to 113,356 shares. The filing states the shares were originally purchased in the open market on 03/01/2024.
NEXGEL (NXGL) CEO and director Adam R. Levy disclosed open‑market sales executed under a Rule 10b5‑1 trading plan.
He sold 1,600 shares on 10/02/2025 at $2.5000 per share and 2,400 shares on 10/03/2025 at a weighted average price of $2.5497, with individual trades ranging from $2.5000 to $2.6100. After these transactions, he beneficially owned 371,692 shares.
Nexgel, Inc. (NXGL) filed a Form 144 reporting a proposed sale of 16,000 common shares with an aggregate market value of $40,000.00. The shares were originally acquired on 10/15/2019 as compensation from the issuer. The filing lists approximately 8,067,580 shares outstanding and names The Charles Schwab Corporation as the broker with an approximate sale date of 10/02/2025 on NASDAQ. The filer also reported a prior sale of 4,000 shares on 08/28/2025 for gross proceeds of $9,896.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
NEXGEL director Henry Scott Robert sold 7,697 shares of the company's common stock on 09/25/2025 under a pre-established Rule 10b5-1 trading plan at a weighted average price of $2.3579 per share. The shares were originally purchased on 03/01/2024. After the sale, the reporting person beneficially owns 121,356 shares, held directly. The filer notes the sale prices ranged from $2.3500 to $2.3900 and offers to provide a breakdown of shares sold at each price if requested.
Form 144 notice for proposed sale of common stock. The filing shows 35,515 shares of common stock are proposed for sale through The Charles Schwab Corporation, with an aggregate market value of $108,451 and 8,067,580 shares outstanding. The securities were acquired as compensation on 02/15/2024 in a transaction described as "COMPENSATION / DEAL ACQUIRED BETWEEN: 2/15/24 TO 11/5/24" and payment is recorded as of 02/15/2024. The filer reports no securities sold during the past three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.